Abstract: A method for monitoring driving performance is provided. The method may include determining an engine fuel efficiency based on an engine speed and power output and determining a transmission fuel efficiency based on a drive ratio. A drive-train fuel efficiency may be determined based on the engine fuel efficiency and transmission fuel efficiency, and the drive-train efficiency may be compared to a target drive-train efficiency.

Abstract: A method of controlling a variable valve actuation system for an engine is provided. A cam assembly is operated to move an intake valve between a first position and a second position. A parameter indicative of an altitude at which the engine is operating is sensed. A first lookup map is accessed to determine a desired air-to-fuel ratio when the sensed parameter indicates that the engine is operating at an altitude below a first predetermined value. A second lookup map is accessed to determine a desired air-to-fuel ratio when the sensed parameter indicates that the engine is operating at an altitude above the first predetermined value. A desired valve actuation period is determined based on the determined air-to-fuel ratio. The intake valve is prevented from returning to the first position until the end of the determined valve actuation period.

Abstract: The present invention provides a method and apparatus for controlling an intake engine valve capable of variable closing timing. A condition indicative of white smoke production is determined. An intake engine valve is closed at a first crank angle for a given engine operating condition when the condition indicative of white smoke production does not exist. The intake valve is closed at a second crank angle for the given engine operating condition when the condition indicative of white smoke production exists. The second crank angle is less than the first crank angle.

Abstract: This invention provides a novel series of non-peptidyl compounds which are useful in the treatment or prevention of a physiological disorder associated with an excess of tachykinins. This invention also provides methods for the treatment of such physiological disorders as well as pharmaceutical formulations which employ these novel compounds.

Abstract: The instant invention provides novel substituted naphthyl compounds, intermediates, compositions, pharmaceutical formulations, and methods of use.

Abstract: This invention provides a novel series of non-peptidyl compounds which are useful in the treatment or prevention of a physiological disorder associated with an excess of tachykinins. This invention also provides methods for the treatment of such physiological disorders as well as pharmaceutical formulations which employ these novel compounds.

Abstract: The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective &bgr;3 receptor agonists useful in the treatment of Type II diabetes and obesity.

Abstract: An apparatus adapted to form curved beam sections, such as a brake shoe, includes a rollformer, a cut-off device, and a re-former or sweeping device. The rollformer includes rollers constructed and arranged to rollform the sheet material into an elongated linear beam, where the beam has a T-shaped cross-section. The cut-off device cuts the arcuately-shaped beam into segments that are about 9 to 12 inches long. The sweep device is positioned in line with the rollformer (or off-line as a secondary operation) and is adapted to form the beam into a tightly-radiused longitudinal shape, such as about 100 mm radius, where the support flange and center web form an arcuate crescent shape. In an alternative form, the apparatus also has a re-forming device configured to reshape the segments so that the beam section is very accurately formed. However, it is contemplated that, depending upon the arcuately shaped beam section desired, a re-former may not be required.

Abstract: The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective &bgr;3 receptor agonists useful in the treatment of Type II diabetes and obesity.

Abstract: Disclosed herein are selective beta 3 adrenergic agonists represented by the following structural formula: The variables in the structural formula shown above are defined in the specification. Also disclosed are methods of using these compounds for agonizing the beta 3 adrenergic receptor in patients in need of such treatment, for example, patients in need of treatment for obesity or Type II diabetes.

Abstract: This invention provides a novel series of non-peptidyl compounds which are useful in the treatment or prevention of a physiological disorder associated with an excess of tachykinins. This invention also provides methods for the treatment of such physiological disorders as well as pharmaceutical formulations which employ these novel compounds.

Abstract: An apparatus adapted to form curved beam sections, such as a brake shoe, includes a rollformer, a cut-off device, and a re-former or sweeping device. The rollformer includes rollers constructed and arranged to rollform the sheet material into an elongated linear beam, where the beam has a T-shaped cross-section. The cut-off device cuts the arcuately-shaped beam into segments that are about 9 to 12 inches long. The sweep device is positioned in line with the rollformer (or off-line as a secondary operation) and is adapted to form the beam into a tightly-radiused longitudinal shape, such as about 100 mm radius, where the support flange and center web form an arcuate crescent shape. In an alternative form, the apparatus also has a re-forming device configured to reshape the segments so that the beam section is very accurately formed. However, it is contemplated that, depending upon the arcuately shaped beam section desired, a re-former may not be required.

Abstract: This invention provides certain sulfonamide compounds, formulations, and a method for treating susceptible neoplasms in mammals using certain sulfonamide compounds.

Abstract: Disclosed herein are selective beta 3 adrenergic agonists represented by the following structural formula: ##STR1## The variables in the structural formula shown above are defined in the specification. Also disclosed are methods of using these compounds for agonizing the beta 3 adrenergic receptor in patients in need of such treatment, for example, patients in need of treatment for obesity or Type II diabetes.

Abstract: This invention provides a novel series of non-peptidyl compounds which are useful in the treatment or prevention of a physiological disorder associated with an excess of tachykinins. This invention also provides methods for the treatment of such physiological disorders as well as pharmaceutical formulations which employ these novel compounds.

Abstract: This invention provides a novel series of non-peptidyl compounds which are useful in the treatment or prevention of a physiological disorder associated with an excess of tachykinins. This invention also provides methods for the treatment of such physiological disorders as well as pharmaceutical formulations which employ these novel compounds.

Abstract: A digital panel meter that is mounted in a panel and that is comprised of a housing for containing a circuit assembly having a digital display at the front of the housing. A bezel is adapted to cover the front of the housing and has a transparent window for the viewing of the digital display. The bezel includes a pair of elongated bezel locking arms that are spacedly disposed and extend towards the rear of the housing where they interlock with the housing. The housing is also provided with locking tabs for securing the housing to the panel.

Abstract: This invention describes a process for selectively preparing trans-1-isopropylsulfonyl-2-amino-6-(1-phenyl-1-propenyl)benzimidazole by dehydrating the corresponding benzimidazole carbinol with certain specific acids.